E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with P
>
Issuers starting with P, PV only
>
All stories on PDL BioPharma, Inc.
>
Stories on PDL BioPharma, Inc., PV only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
PDL BioPharma, Inc.
4/9/2014
PV
New Issue: kaleo secures $150 million of 13% financing from PDL BioPharma
11/6/2013
PV
New Issue: Durata Therapeutics arranges $70 million of debt financing with PDL
11/5/2013
PV
New Issue: Direct Flow Medical arranges $50 million of debt financing with PDL
12/31/2009
PV
Dow's $4.5 billion private placement tops list of 2009 notable deals
10/28/2009
HYPV
New Issue: PDL BioPharma subsidiary to issue $300 million 10.25% notes due 2015
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
